Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

New weight loss drugs like Ozempic and Wegovy help suppress appetite, leading to significant weight loss, but they come with ...

The FBI has issued a warning about counterfeit versions of compounded weight loss drugs, which have been found to contain ...

Dawn Maroney became president of Alignment Health in January at a critical time for the health insurance industry.

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...